Cost–Effectiveness of Angiotensin-converting Enzyme Inhibitors in Nondiabetic Advanced Renal Disease

Charles Christian Adarkwah; Afschin Gandjour


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(2):215-223. 

In This Article

Five-year View

We expect that the potential for savings by preventing ESRD will increase in the future. In the last 10 years, dialysis costs have increased by approximately 25%[26,30,43,101] and we expect this trend to continue owing to stricter regulations concerning dialysis safety, technological advancement of dialysis machines and better-tolerated dialysis solutions. On the other hand, the prices of erythropoietin and reimbursement of physicians may decrease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.